Quick Answer
Cell Source, Inc. reported Net Income of -$5.32 million for fiscal year 2023.
Cell Source, Inc. — Key Financials by Year
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Net Income | -$5.32M -3.0% |
-$5.17M +5.6% |
-$5.47M -20.0% |
-$4.56M -1.9% |
-$4.48M -111.4% |
-$2.12M +31.3% |
| Diluted EPS | -$0.17 +5.6% |
-$0.18 +5.3% |
-$0.19 | — | — | — |
| Total Assets | $195.2K -52.4% |
$409.8K +30.6% |
$313.8K -30.6% |
$452.3K +294.1% |
$114.8K +74.5% |
$65.8K -87.6% |
| Cash and Equivalents | — | $222.7K +139.2% |
$93.1K -61.5% |
$241.6K +765.8% |
$27.9K +47.4% |
$18.9K -94.9% |
| Stockholders Equity | -$15.61M -23.6% |
-$12.63M -28.6% |
-$9.83M -23.6% |
-$7.95M -38.4% |
-$5.74M -16.7% |
-$4.92M -8.0% |
| R&D Expense | — | $1.94M +52.2% |
$1.27M +52.5% |
$834.9K -66.0% |
$2.46M +793.7% |
$274.9K -56.9% |
| Operating Income | -$4.33M -3.6% |
-$4.18M -3.9% |
-$4.02M -10.5% |
-$3.64M +4.4% |
-$3.81M -89.7% |
-$2.01M +12.5% |
| Shares Outstanding | 39.83M +10.4% |
36.08M +5.0% |
34.36M +5.6% |
32.54M +20.2% |
27.08M +3.8% |
26.08M +2.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2024 | -$1.42M | -5.9% | +4.8% |
| Diluted EPS | September 30, 2024 | -$0.04 | +0.0% | +0.0% |
| Total Assets | September 30, 2024 | $264.7K | +6.6% | -38.4% |
| Cash and Equivalents | June 30, 2023 | $22.0K | +746.9% | -83.5% |
| Stockholders Equity | September 30, 2024 | -$18.94M | -18.2% | -9.4% |
| R&D Expense | September 30, 2022 | $468.0K | +4.8% | -15.7% |
| Operating Income | September 30, 2024 | -$831.6K | +16.5% | +30.3% |
| Shares Outstanding | September 30, 2024 | 43.25M | +12.4% | +3.1% |
- Cell Source, Inc. reported Net Income of -$5.32 million for fiscal year 2023.
- Cell Source, Inc. showed a decrease of -3.0% in Net Income compared to the prior fiscal year.
- Cell Source, Inc. reported Diluted EPS of $0.17 per share (loss) for fiscal year 2023.
- Cell Source, Inc. showed an increase of +5.6% in Diluted EPS compared to the prior fiscal year.
- Cell Source, Inc. reported Total Assets of $195.2 thousand for fiscal year 2023.
- Cell Source, Inc. showed a decrease of -52.4% in Total Assets compared to the prior fiscal year.
- Cell Source, Inc. reported Cash and Equivalents of $222.7 thousand for fiscal year 2022.
- Cell Source, Inc. showed an increase of +139.2% in Cash and Equivalents compared to the prior fiscal year.
- Cell Source, Inc. reported Stockholders Equity of -$15.61 million for fiscal year 2023.
- Cell Source, Inc. showed a decrease of -23.6% in Stockholders Equity compared to the prior fiscal year.
- Cell Source, Inc. reported R&D Expense of $1.94 million for fiscal year 2022.
- Cell Source, Inc. showed an increase of +52.2% in R&D Expense compared to the prior fiscal year.
- Cell Source, Inc. reported Operating Income of -$4.33 million for fiscal year 2023.
- Cell Source, Inc. showed a decrease of -3.6% in Operating Income compared to the prior fiscal year.
- Cell Source, Inc. reported Shares Outstanding of 39.83 million shares for fiscal year 2023.
- Cell Source, Inc. showed an increase of +10.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: